Publications in collaboration with researchers from University Medical Center Utrecht (19)

2024

  1. Effects of cannabidiol on symptoms in people at clinical high risk for psychosis

    World Psychiatry

  2. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol

    Psychological Medicine, Vol. 54, Núm. 5, pp. 993-1003

2023

  1. Hippocampal Glutamate, Resting Perfusion and the Effects of Cannabidiol in Psychosis Risk

    Schizophrenia Bulletin Open, Vol. 4, Núm. 1

2022

  1. Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 272, Núm. 3, pp. 461-475

2021

  1. Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function

    Translational Psychiatry, Vol. 11, Núm. 1

  2. Correction: Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function (Translational Psychiatry, (2021), 11, 1, (579), 10.1038/s41398-021-01705-z)

    Translational Psychiatry

  3. Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis

    Human Brain Mapping, Vol. 42, Núm. 2, pp. 439-451

  4. Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes

    Neuropsychopharmacology, Vol. 46, Núm. 8, pp. 1468-1474

2020

  1. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis

    Translational Psychiatry, Vol. 10, Núm. 1

  2. Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study

    Neuropsychopharmacology, Vol. 45, Núm. 4, pp. 641-648

  3. Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association with Clinical Outcome

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 670-679

2019

  1. Association of Hippocampal Glutamate Levels with Adverse Outcomes in Individuals at Clinical High Risk for Psychosis

    JAMA Psychiatry

  2. Basic self-disturbances related to reduced anterior cingulate volume in subjects at ultra-high risk for psychosis

    Frontiers in Psychiatry, Vol. 10, Núm. MAY

  3. Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis

    Translational Psychiatry, Vol. 9, Núm. 1

2018

  1. Correction to: Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis (Neuropsychopharmacology, (2018), 43, 13, (2652-2659), 10.1038/s41386-017-0004-6)

    Neuropsychopharmacology

  2. Cortical GABA in subjects at ultra-high risk of psychosis: Relationship to negative prodromal symptoms

    International Journal of Neuropsychopharmacology, Vol. 21, Núm. 2, pp. 114-119

  3. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial

    JAMA Psychiatry, Vol. 75, Núm. 11, pp. 1107-1117

  4. Increased resting hippocampal and basal ganglia perfusion in people at ultra high risk for psychosis: Replication in a second cohort

    Schizophrenia Bulletin, Vol. 44, Núm. 6, pp. 1323-1331

  5. Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis

    Neuropsychopharmacology, Vol. 43, Núm. 13, pp. 2652-2659